Thomas E Stinchcombe Selected Research

Ovarian Neoplasms (Ovarian Cancer)

1/2021	Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients.
10/2007	Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas E Stinchcombe Research Topics

Disease

86	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 12/2004
43	Neoplasms (Cancer) 06/2022 - 03/2005
16	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2005
15	Disease Progression 01/2022 - 01/2008
12	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 04/2005
7	Leukemia 07/2017 - 11/2008
6	Neutropenia 11/2020 - 04/2005
5	Fatigue 01/2021 - 11/2002
5	Exanthema (Rash) 12/2020 - 04/2005
4	Adenocarcinoma 06/2022 - 06/2012
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 12/2013
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 11/2002
4	Diarrhea 12/2020 - 04/2005
4	Neoplasm Metastasis (Metastasis) 11/2019 - 11/2006
3	Thrombocytopenia (Thrombopenia) 01/2021 - 11/2002
3	Hypertension (High Blood Pressure) 10/2019 - 04/2009
3	Brain Neoplasms (Brain Tumor) 05/2013 - 04/2009
3	Hypersensitivity (Allergy) 08/2007 - 11/2002
2	Cardiotoxicity 01/2022 - 05/2017
2	Carcinoma (Carcinomatosis) 01/2021 - 07/2017
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 10/2007
2	Anemia 11/2020 - 01/2017
2	Malignant Mesothelioma 11/2020 - 01/2017
2	Mucositis 01/2017 - 04/2005
2	Breast Neoplasms (Breast Cancer) 10/2007 - 08/2007
1	Lymphoma (Lymphomas) 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Central Nervous System Diseases (CNS Diseases) 01/2021
1	Lymphopenia (Lymphocytopenia) 11/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	COVID-19 01/2020
1	Proteinuria 10/2019

Drug/Important Bio-Agent (IBA)

15	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 02/2006
14	PlatinumIBA 09/2021 - 04/2005
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 03/2005
11	Pemetrexed (MTA)FDA Link 11/2020 - 04/2005
10	ErbB Receptors (EGF Receptor)IBA 10/2019 - 09/2008
9	Bevacizumab (Avastin)FDA Link 10/2019 - 09/2007
8	Biomarkers (Surrogate Marker)IBA 02/2022 - 10/2009
8	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2011
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 09/2011
5	Gemcitabine FDA Link 04/2013 - 03/2005
5	Gefitinib (Iressa)FDA Link 06/2012 - 06/2006
5	Docetaxel (Taxotere)FDA Link 09/2008 - 04/2005
4	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2015
4	Pharmaceutical PreparationsIBA 05/2017 - 12/2004
3	B7-H1 AntigenIBA 06/2022 - 07/2017
3	pembrolizumabIBA 06/2022 - 08/2021
3	Circulating Tumor DNAIBA 01/2022 - 10/2019
3	osimertinibIBA 01/2021 - 02/2016
3	Cetuximab (Erbitux)FDA Link 12/2020 - 08/2007
3	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 02/2011
3	Anaplastic Lymphoma KinaseIBA 01/2016 - 01/2011
3	Albumin-Bound Paclitaxel FDA Link 02/2015 - 10/2007
2	brigatinibIBA 01/2022 - 01/2021
2	LigandsIBA 01/2022 - 01/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2021
2	NivolumabIBA 09/2021 - 03/2015
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 12/2017
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2017
2	Cell-Free Nucleic AcidsIBA 10/2019 - 01/2019
2	Immunoglobulin G (IgG)IBA 07/2017 - 03/2015
2	Sunitinib (Sutent)FDA Link 01/2017 - 02/2014
2	Monoclonal AntibodiesIBA 01/2014 - 11/2010
2	vinflunineIBA 10/2011 - 02/2011
2	Cisplatin (Platino)FDA LinkGeneric 02/2011 - 11/2008
2	SolventsIBA 05/2008 - 10/2007
2	130-nm albumin-bound paclitaxelIBA 05/2008 - 08/2007
2	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 09/2007
1	atezolizumabIBA 06/2022
1	alectinibIBA 01/2022
1	niraparibIBA 01/2022
1	Histocompatibility Antigens Class IIBA 10/2021
1	IpilimumabIBA 09/2021
1	navitoclaxIBA 01/2021
1	durvalumabIBA 01/2021
1	telisotuzumab vedotinIBA 01/2021
1	tremelimumabIBA 01/2021
1	veliparibIBA 01/2021
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2021
1	talazoparibIBA 01/2021
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021
1	AfatinibIBA 12/2020
1	tributyl phosphate (TBP)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Ado-Trastuzumab EmtansineIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2018

Therapy/Procedure

49	Therapeutics 06/2022 - 11/2002
28	Drug Therapy (Chemotherapy) 09/2021 - 02/2006
21	Radiotherapy 01/2022 - 07/2006
8	Immunotherapy 02/2022 - 05/2014
8	Chemoradiotherapy 01/2021 - 09/2009
5	Combined Modality Therapy 01/2019 - 04/2006
4	Induction Chemotherapy 09/2017 - 03/2008
3	Adjuvant Chemotherapy 01/2022 - 09/2007
2	Cranial Irradiation 01/2019 - 07/2010
2	Conformal Radiotherapy 11/2011 - 01/2009
2	Maintenance Chemotherapy 10/2009 - 02/2009
1	Lymph Node Excision (Lymph Node Dissection) 01/2022